Research Activity – Page 7

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial

2 months ago talkbio0Tagged Clinical Research, Effect, Failure (biologic function), MADRS score, Placebos, SPN-820, Supernus Pharmaceuticals, treatment-resistant depression

Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect

Cabaletta’s CABA-201 CAR-T Therapy Shows Promising Results in Lupus and Other Autoimmune Diseases

2 months ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, CABA-201, CAR-T, Clinical Trials, Lupus Vulgaris

CABA-201, CAR-T therapy, lupus, autoimmune diseases, clinical trials, remission, B cell depletion

Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint

2 months ago talkbio0Tagged Clinical Trials, decline, Effect, Failure (biologic function), Placebos, SPN-820, Supernus Pharmaceuticals, treatment-resistant depression

Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

2 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

Major Budget Cuts and Layoffs Hit US Health Agencies: Impacts on CDC, NIH, and Public Health

2 months ago talkbio0Tagged Administration occupational activities, Centers for Disease Control and Prevention (U.S.), healthcare budget, layoffs, Medical Research activity, NIH Mouse, public health medicine (field), Transplant Registry Unified Management Program

healthcare budget cuts, CDC layoffs, NIH funding reduction, public health impact, Trump administration, federal workforce reduction, medical research funding

Solid Biosciences’ DMD Gene Therapy Shows Promising Early Results, Driving Stock Surge

2 months ago talkbio0Tagged Clinical Trials, gene therapy, Muscular Dystrophy, Duchenne, SGT-003, Solid Biosciences, surge

Duchenne muscular dystrophy (DMD), gene therapy, SGT-003, microdystrophin, clinical trial, stock surge, Solid Biosciences

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

2 months ago talkbio0Tagged Arbitrating, asset, Biosciences, Clinical Trials, Failure (biologic function), Fraud, Freezing, Hypertensive disease, kilobase pairs, Nordisk, Ocedurenone

Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration

Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Cancer Vaccines, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Discovery, Gene Modification, Investments, personalized therapies, Platform technologies, Precision Medicine, solid-state batteries

CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation

Arcus Biosciences Advances Promising Kidney Cancer Drug Casdatifan After Gilead Opts Out

2 months ago talkbio0Tagged Arcus, casdatifan, cell renal cell carcinoma, Clinical Trials, Conventional (Clear Cell) Renal Cell Carcinoma, HIF-2a, Inhibitor, Malignant neoplasm of kidney

Arcus Biosciences, casdatifan, HIF-2a inhibitor, kidney cancer, clear cell renal cell carcinoma (ccRCC), Gilead Sciences, clinical trial data, $150 million stock offering